114425-49-9

Basic information

• Product Name: PHENYLMETHYLPHOSPHINIC ACID ETHYL ESTER
• Synonyms: PHENYLMETHYLPHOSPHINIC ACID ETHYL ESTER;Ethyl Benzylphosphinate
• CAS NO: 114425-49-9
• Molecular Formula: C₉H₁₃O₂P
• Molecular Weight: 184.172081
• Mol File: 114425-49-9.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: PHENYLMETHYLPHOSPHINIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: PHENYLMETHYLPHOSPHINIC ACID ETHYL ESTER(114425-49-9)
• EPA Substance Registry System: PHENYLMETHYLPHOSPHINIC ACID ETHYL ESTER(114425-49-9)

Safety Data

• Hazardous Substances Data: 114425-49-9(Hazardous Substances Data)

Upstream product

• 20394-86-9 benzylphosphinic acid 
• 541-41-3 chloroformic acid ethyl ester 
• 14684-32-3 ethyl phosphinate 
• 100-39-0 benzyl bromide 

Downstream Products

• 57539-15-8 1-ethoxy-2,2,4-trimethyl-5-phenyl-2,3-dihydro-1H-phosphole 1-oxide 
• 58194-91-5 Benzyl-(phenyl-{N'-[1-phenyl-meth-(E)-ylidene]-hydrazino}-methyl)-phosphinic acid ethyl ester 
• 1027236-48-1 ethyl benzyl(2-cyanoethyl)phosphinate 
• 872471-58-4 ethyl (+/-)-4-(tert-butyldimethylsiloxy)cyclopent-1-enyl(benzyl)phosphinate 
• 1017965-04-6 C₃₂H₃₉NO₁₁P₂ 
• 139668-40-9 ethyl (3-chloro-2(R)-hydroxypropyl)benzylphosphinate 
• 206648-49-9 Ethyl P-benzyl-N-(2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl)aminomethylphosphinate 
• 1026739-18-3 (3-Amino-propyl)-benzyl-phosphinic acid ethyl ester 
• 848773-38-6 C₁₂H₂₁O₂PSi 

Relevant articles and documents

DBU-promoted alkylation of alkyl phosphinates and H-phosphonates

The alkylation of alkyl phosphinates and some H-phosphonate diesters is promoted by the base DBU. Only more reactive alkyl halides react in preparatively useful yields. However, the method provides easy access to important H-phosphinate building blocks, without the need for a protecting group strategy or metal catalysts. The reaction is conveniently conducted at, or below, room temperature. The preparation of methyl-H-phosphinate esters is particularly interesting as it avoids the heretofore more common use of methyldichlorophosphine MePCl2.

Recent advances in phosphorus-carbon bond formation: Synthesis of H-phosphinic acid derivatives from hypophosphorous compounds

This account summarizes the research conducted in our laboratory over the past five years. New methodologies were devised for the formation of P-C bonds with a focus on the reactions of hypophosphorous acid derivatives. Three types of reactions have been developed: palladium-catalyzed cross-coupling, room-temperature radical addition, and palladium-catalyzed addition. Our results are summarized in each of these areas and include some of our most recent data. (1) Our palladium-catalyzed cross-coupling has been extended to the direct coupling of alkyl phosphinates with a variety of aryl, heteroaryl, and even alkenyl electrophiles. (2) The addition of sodium hypophosphite under radical conditions is extended from alkenes to alkynes. (3) The catalytic addition of hypophosphorous compounds using palladium catalysts (hydrophosphinylation) is also discussed.

Certain N-substituted-amino-alkane phosphinic acid derivatives having anti-epileptic properties

Compounds having GABAB -antagonistic properties, for example those of formula I STR1 wherein one of the radicals R1, R2 and R3 is hydrogen or an aliphatic, cycloaliphatic, araliphatic or aromatic radical, another is hydrogen or, in the case of R1 or R2, hydroxy or, in the case of R1, halogen or, in the case of R2 together with R2 ', oxo, and the remaining radical is hydrogen, R1 ' is hydrogen or halogen, R2 ' is hydrogen, hydroxy or, together with R2, is oxo, R4 and R5 are hydrogen or R4 is an araliphatic or heteroarylaliphatic radical and R5 is hydrogen or an aliphatic radical, and R is an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, araliphatic, heteroarylaliphatic or aromatic radical having at least 2 carbon atoms or, when R1 is hydrogen or hydroxy, R2 is an aromatic radical and R1 ', R2 ' and R3 are hydrogen, R is methyl, and their pharmaceutically acceptable salts, can be used as active ingredients in medicaments for the treatment of epilepsies of the "petit mal" type. The invention relates also to novel compounds of formula I and processes for the preparation thereof.